AnalystsChristopher LiuChristopher Liu's Stock Forecasts
AnalystsChristopher Liu
Sectors:
Industries:
Analyst Ranking
Top 32%
#1767 out of 5511 analysts
Average Return
+30.17%
Win Rate
56%5 out of 9
Risk vs Reward
Poor
Good
Christopher Liu's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Faeth Therapeutics IncFTH | +101.08% | $17.59 | $35.37 | 2026-05-28 - 2026-09-15 | Strong Buy |
Relay Therapeutics IncRLAY | +78.36% | $4.39 | $7.83 | 2024-12-04 - 2025-12-03 | Buy |
Ideaya Biosciences IncIDYA | +65.71% | $21.64 | $35.86 | 2023-08-08 - 2024-08-07 | Buy |
Exelixis IncEXEL | +57.49% | $36.13 | $56.90 | 2025-10-21 - 2026-09-15 | Buy |
Adagene IncADAG | +43.48% | $2.07 | $2.97 | 2025-09-18 - 2026-09-15 | Strong Buy |
Christopher Liu Analyst Color
Get additional color on Christopher Liu's coverage of popular stocks
Christopher Liu's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Faeth Therapeutics IncFTH | 1 | Strong Buy | $50.00 | +41.36% | Initiates Coverage On | 4 months ago |
Nextcure IncNXTC | 1 | Strong Buy | $25.00 | +292.46% | Initiates Coverage On | 4 months ago |
Relmada Therapeutics IncRLMD | 1 | Strong Buy | $14.00 | +215.32% | Initiates Coverage On | 6 months ago |
Exelixis IncEXEL | 2 | Buy | $48.00 | -15.64% | Upgrades | a year ago |
Lyell Immunopharma IncLYEL | 1 | Strong Buy | $20.00 | +83.32% | Initiates Coverage On | a year ago |
Adagene IncADAG | 1 | Strong Buy | $9.00 | +203.03% | Initiates Coverage On | a year ago |
Genelux CorpGNLX | 1 | Strong Buy | $10.00 | N/A | Initiates Coverage On | a year ago |
Relay Therapeutics IncRLAY | 1 | Buy | $18.00 | N/A | Maintains | 2 years ago |
Ideaya Biosciences IncIDYA | 2 | Hold | $27.00 | N/A | Downgrades | 2 years ago |
Nuvalent IncNUVL | 1 | Hold | $42.00 | N/A | Initiates Coverage On | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.